Blasiak Barbara, Landry James, Tyson Randy, Sharp Jonathan, Iqbal Umar, Abulrob Abedelnasser, Rushforth David, Matyas John, Ponjevic Dragana, Sutherland Garnette R, Wolfsberger Stefan, Tomanek Boguslaw
Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada; Polish Academy of Sciences, Institute of Nuclear Physics, Krakow, 152 Radzikowskiego, Krakow, Malopolska 31-342, Poland.
Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada.
J Neurosci Methods. 2014 Apr 15;226:132-138. doi: 10.1016/j.jneumeth.2014.01.034. Epub 2014 Feb 10.
Glioma is the most common and most difficult to treat brain cancer. Despite many efforts treatment, efficacy remains low. As neurosurgical removal is the standard procedure for glioma, a method, allowing for both early detection and exact determination of the location, size and extent of the tumor, could improve a patient's positive response to therapy.
We propose application of susceptibility weighted molecular magnetic resonance imaging using, targeted contrast agents, based on superparamagnetic iron oxide nanoparticles, for imaging of the, glioma rim, namely brain-tumor interface. Iron oxide attached to the targeted cells increases, susceptibility differences at the boundary between tumor and normal tissue, providing the opportunity, to utilize susceptibility weighted imaging for improved tumor delineation. We investigated potential, enhancement of the tumor-brain contrast, including tumor core and rim when using susceptibility, weighted MRI for molecular imaging of glioma.
There were significant differences in contrast-to-noise ratio before, 12 and 120min after contrast, agent injection between standard gradient echo pulse sequence and susceptibility weighted molecular, magnetic resonance imaging for the core-brain, tumor rim-core and tumor rim-brain areas.
Currently, the most common MRI contrast agent used for glioma diagnosis is a non-specific, gadolinium-based agent providing T1-weighted enhancement. Susceptibility-weighted magnetic, resonance imaging is much less efficient when no targeted superparamagnetic contrast agents are, used.
The improved determination of glioma extent provided by SWI offers an important new tool for, diagnosis and surgical planning.
胶质瘤是最常见且最难治疗的脑癌。尽管进行了许多治疗努力，但疗效仍然很低。由于神经外科切除是胶质瘤的标准治疗方法，一种能够实现早期检测并精确确定肿瘤位置、大小和范围的方法，可能会提高患者对治疗的积极反应。
我们提出应用基于超顺磁性氧化铁纳米颗粒的靶向造影剂进行敏感性加权分子磁共振成像，用于胶质瘤边缘即脑肿瘤界面的成像。附着在靶向细胞上的氧化铁会增加肿瘤与正常组织边界处的敏感性差异，从而有机会利用敏感性加权成像来更好地勾勒肿瘤轮廓。我们研究了在使用敏感性加权磁共振成像进行胶质瘤分子成像时，包括肿瘤核心和边缘在内的肿瘤与脑对比度的潜在增强情况。
在注射造影剂前、注射后12分钟和120分钟，标准梯度回波脉冲序列与敏感性加权分子磁共振成像在核心与脑、肿瘤边缘与核心以及肿瘤边缘与脑区域之间的对比噪声比存在显著差异。
目前，用于胶质瘤诊断的最常见磁共振成像造影剂是一种非特异性的基于钆的造影剂，可提供T1加权增强。当不使用靶向超顺磁性造影剂时，敏感性加权磁共振成像的效率要低得多。
敏感性加权成像（SWI）对胶质瘤范围的更好确定为诊断和手术规划提供了一种重要的新工具。
